Lexicon Pharmaceuticals (LXRX) Assets Average (2011 - 2026)

Lexicon Pharmaceuticals (LXRX) has 16 years of Assets Average data on file, last reported at $226.9 million in Q1 2026.

• Assets Average for Q1 2026 came in at $226.9 million, down 23.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $226.9 million (down 23.87% YoY), and the FY2025 annual result was $241.7 million, down 8.42% from the prior year.
• Assets Average climbed to $226.9 million in Q1 2026 per LXRX's latest filing, from $195.5 million in the prior quarter.
• Over five years, Assets Average peaked at $395.3 million in Q2 2024 and troughed at $124.3 million in Q2 2022.
• A 5-year average of $243.9 million and a median of $239.7 million in 2023 frame the typical range for Assets Average.
• The sharpest annual moves came in 2023 and 2025: Assets Average surged 95.13% in 2023, then tumbled 37.87% in 2025.
• A 5-year view of Assets Average shows it stood at $193.0 million in 2022, then surged by 31.07% to $253.0 million in 2023, then rose by 22.46% to $309.8 million in 2024, then slumped by 36.9% to $195.5 million in 2025, then rose by 16.09% to $226.9 million in 2026.
• Business Quant data shows LXRX's Assets Average at $226.9 million in Q1 2026, $195.5 million in Q4 2025, and $215.8 million in Q3 2025.